Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies

Leukemia Research Reports(2021)10.1016/j.lrr.2021.100268Source: DataRank Database

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies is a research paper published in Leukemia Research Reports (2021). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.39)OA: goldTopics (21)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Yixuan Chen ORCID,Berit Lubben,Ola Adebayo ORCID,Barbara Muz ORCID,Abdel Kareem Azab ORCID

Live enrichment

PubMed:34584838 PMC:PMC8455363 OpenAlex:https://openalex.org/W3199671843

National Cancer Institute

Grant: U54CA199092

National Institutes of Health

Grant: 1U54CA199092-01

Developmental Project

Washington University in St. Louis

National Institutes of Health

FWCI

1.39

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.sciencedirect.com/science/article/pii/S2213048921000352/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2213048921000352/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2213048921000352?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213048921000352?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.lrr.2021.100268

Fields of Study

Phagocytosis and Immune RegulationErythrocyte Function and PathophysiologyImmunotherapy and Immune Responses0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

CD47Monoclonal antibodyMedicineAntibodyImmune checkpointImmune systemImmunologyCancer researchImmunotherapyMacrophageHematologic MalignanciesCheckpoint InhibitionNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies

FAIR Checklist

Authors (6)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)